CN113939540A - 抗IgE抗体 - Google Patents

抗IgE抗体 Download PDF

Info

Publication number
CN113939540A
CN113939540A CN202080038130.8A CN202080038130A CN113939540A CN 113939540 A CN113939540 A CN 113939540A CN 202080038130 A CN202080038130 A CN 202080038130A CN 113939540 A CN113939540 A CN 113939540A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080038130.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·桑德斯
R·比吉里玛纳
C·布朗什托
M·克伦姆赫克
C·麦圭尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
Argus Iip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argus Iip filed Critical Argus Iip
Publication of CN113939540A publication Critical patent/CN113939540A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080038130.8A 2019-04-11 2020-04-09 抗IgE抗体 Pending CN113939540A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1905150.7 2019-04-11
GB1905150.7A GB2589049C (en) 2019-04-11 2019-04-11 Anti-IgE antibodies
PCT/EP2020/060240 WO2020208177A1 (en) 2019-04-11 2020-04-09 ANTI-IgE ANTIBODIES

Publications (1)

Publication Number Publication Date
CN113939540A true CN113939540A (zh) 2022-01-14

Family

ID=66809886

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080038130.8A Pending CN113939540A (zh) 2019-04-11 2020-04-09 抗IgE抗体

Country Status (16)

Country Link
US (3) US20220177604A1 (https=)
EP (1) EP3953396A1 (https=)
JP (1) JP7586833B2 (https=)
KR (1) KR20210150430A (https=)
CN (1) CN113939540A (https=)
AU (1) AU2020271405A1 (https=)
BR (1) BR112021020329A2 (https=)
CA (1) CA3133941A1 (https=)
EA (1) EA202192785A1 (https=)
GB (1) GB2589049C (https=)
IL (1) IL287035A (https=)
MA (1) MA55600A (https=)
MX (1) MX2021012457A (https=)
PH (1) PH12021552545A1 (https=)
SG (1) SG11202110247XA (https=)
WO (1) WO2020208177A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
AU2022310356A1 (en) 2021-07-14 2024-01-25 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
EP4431528A1 (en) * 2021-10-29 2024-09-18 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
GB2635291A (en) 2022-07-01 2025-05-07 Alk Abello As Displacers of IgE-FCERI
CN115724951B (zh) * 2022-11-15 2023-10-03 怡道生物科技(苏州)有限公司 与11型hpv结合的抗体或其抗原结合片段及其应用
JP2026503461A (ja) * 2023-01-18 2026-01-29 ライシア セラピューティクス， インコーポレイテッド サイクリングリソソーム標的化抗体コンジュゲート
CN118725128B (zh) * 2023-03-28 2025-09-16 东莞市朋志生物科技有限公司 抗IgE抗体、检测IgE的试剂和试剂盒
CN119490594B (zh) * 2023-08-15 2025-09-16 东莞市朋志生物科技有限公司 一种抗免疫球蛋白e的抗体及其应用
EP4530295A3 (en) * 2023-09-07 2025-05-28 argenx BV Fcrn antagonists and methods of use
GB202318512D0 (en) * 2023-12-04 2024-01-17 argenx BV Methods of determining potency
WO2025229224A1 (en) * 2024-05-03 2025-11-06 argenx BV Monovalent anti-iga binding molecules and methods of use
US12509529B2 (en) 2024-05-17 2025-12-30 Excellergy, Inc. Antibodies and antibody fragments that bind IgE
WO2025255496A1 (en) * 2024-06-07 2025-12-11 Nuvig Therapeutics, Inc. Modified fc polypeptides
WO2026015664A1 (en) * 2024-07-10 2026-01-15 Lycia Therapeutics, Inc. Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103476A (zh) * 2013-12-24 2016-11-09 阿尔金-X有限公司 FcRn拮抗剂及使用方法
CN106459215A (zh) * 2014-04-30 2017-02-22 韩诺生物制药株式会社 治疗自身免疫疾病的结合fcrn的抗体
US20180222965A1 (en) * 2013-03-15 2018-08-09 Xencor, Inc. Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2467781C (en) 2000-11-20 2014-09-23 Canadian Blood Services Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2004062619A2 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF
SI2000481T1 (sl) 2003-02-01 2016-08-31 Tanox, Inc. Anti-humana protitelesa IgE z visoko afiniteto
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
MY188761A (en) * 2015-03-09 2021-12-29 Argenx Bvba Method of reducing serum levels of fc-containing agents using fcrn antagonists
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
GB201707484D0 (en) * 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180222965A1 (en) * 2013-03-15 2018-08-09 Xencor, Inc. Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
CN106103476A (zh) * 2013-12-24 2016-11-09 阿尔金-X有限公司 FcRn拮抗剂及使用方法
CN106459215A (zh) * 2014-04-30 2017-02-22 韩诺生物制药株式会社 治疗自身免疫疾病的结合fcrn的抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEUNG Y. CHU ET AL.: "Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcgRIIb with Fc-engineered antibody", J ALLERGY CLIN IMMUNOL, vol. 129, no. 4, pages 1102, XP002747319, DOI: 10.1016/J.JACI.2011.11.029 *

Also Published As

Publication number Publication date
GB2589049A (en) 2021-05-26
JP7586833B2 (ja) 2024-11-19
GB201905150D0 (en) 2019-05-29
US20250388700A1 (en) 2025-12-25
PH12021552545A1 (en) 2022-07-04
EP3953396A1 (en) 2022-02-16
SG11202110247XA (en) 2021-10-28
MA55600A (fr) 2022-02-16
AU2020271405A1 (en) 2021-10-14
WO2020208177A1 (en) 2020-10-15
US20220177604A1 (en) 2022-06-09
GB2589049C (en) 2024-02-21
MX2021012457A (es) 2022-01-04
EA202192785A1 (ru) 2022-03-03
GB2589049B (en) 2023-12-13
JP2022528927A (ja) 2022-06-16
CA3133941A1 (en) 2020-10-15
BR112021020329A2 (pt) 2021-12-14
US20250388699A1 (en) 2025-12-25
KR20210150430A (ko) 2021-12-10
IL287035A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
JP7586833B2 (ja) 抗ＩｇＥ抗体
JP7050191B2 (ja) ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
CN106103476B (zh) FcRn拮抗剂及使用方法
JP7789236B2 (ja) Ｆｃｒｎ／ｈｓａ結合分子及び使用方法
JP7163275B2 (ja) 抗－ｉｌ－２２ｒ抗体
WO2025133202A1 (en) Monovalent molecules binding to iga and methods of use
HK40058421A (en) Anti-ige antibodies
EA049400B1 (ru) Антитела к ige
HK40117118A (zh) Fcrn/hsa结合分子及使用方法
HK40117079A (zh) Fcrn/抗原结合分子及使用方法
HK40034924B (zh) Fcrn拮抗剂及使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058421

Country of ref document: HK

CB02 Change of applicant information

Address after: Ghent

Applicant after: Agnes Benelux Co.

Address before: Ghent

Applicant before: Argus IIP

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20230619

Address after: Tianjin Weinalade Belgium

Applicant after: Argenx Bvba

Address before: Ghent

Applicant before: Agnes Benelux Co.

TA01 Transfer of patent application right